FAK and Interacting Proteins as Therapeutic Targets in Pancreatic Cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 10, 2010, Pages 742-746

  Ucar, Deniz A ^a   Hochwald, Steven N ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Molecular Genetics and Microbiology   (United States)

Author keywords

Focal Adhesion Kinase; Pancreatic Cancer; Review

Indexed keywords

1,2,4,5 BENZENETETRAAMINE TETRAHYDROCHLORIDE; 2 [5 CHLORO 2 (2 METHOXY 4 MORPHOLINOANILINO) 4 PYRIMIDINYLAMINO] N METHYLBENZAMIDE; 6 [4 [3 (METHYLSULFONYL)BENZYLAMINO] 5 (TRIFLUOROMETHYL)PYRIMIDIN 2 YL] 3,4 DIHYDROQUINOLON 2(1H)ONE; ANTINEOPLASTIC AGENT; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; GEMCITABINE; GSK 2256098; N METHYL N[3 [[2 (2 OXO 2,3 DIHYDRO 1H INDOL 5 YLAMINO] 5 TRIFLUOROMETHYL PYRIMIDIN 4 YLAMINO]METHYL]PYRIDIN 2 YL]METHANESULFONAMIDE; PF 562 271; PF 573 228; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; Y 15;

AMINO TERMINAL SEQUENCE; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RESISTANCE; CHEMOSENSITIZATION; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENE SILENCING; HEAD AND NECK CANCER; HUMAN; IC 50; IN VIVO STUDY; LUNG CANCER; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREAS TUMOR; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RNA INTERFERENCE; SARCOMA; TUMOR;

EID: 79952763596     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010794728675     Document Type: Article

References (28)

1. Ucar, D.A.; Dang, L.; Hochwald, S.N. FAK signaling and function in pancreatic cancer. Front Biosci., 2011, 3(1), 750-6.
2. Almoguera, C.; Shibata, D.; Forrester, K.; Martin, J.; Arnheim, N.; Perucho, M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 1988, 53(4), 549-54.
3. Blanck, H.M.; Tolbert, P.E.; Hoppin, J.A. Patterns of genetic alterations in pancreatic cancer: a pooled analysis. Environ. Mol. Mutagen., 1999, 33(2), 111-22.
4. Caldas, C.; Hahn, S.A.; da Costa, L.T.; Redston, M.S.; Schutte, M.; Seymour, A.B.; Weinstein, C.L.; Hruban, R.H.; Yeo, C.J.; Kern, S.E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 1994, 8(1), 27-32.
5. Mahlamaki, E.H.; Barlund, M.; Tanner, M.; Gorunova, L.; Hoglund, M.; Karhu, R.; Kallioniemi, A. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer, 2002, 35(4), 353-8.
6. Ischenko, I.; Guba, M.; Yezhelyev, M.; Papyan, A.; Schmid, G.; Green, T.; Fennell, M.; Jauch, K.W.; Bruns, C.J. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis, 2007, 10(3), 167-82.
7. Duxbury, M.S.; Ito, H.; Zinner, M.J.; Ashley, S.W.; Whang, E.E. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin. Cancer Res., 2004, 10(7), 2307-18.
8. Burridge, K.; Turner, C.E.; Romer, L.H. Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly. J. Cell Biol., 1992, 119(4), 893-903.
9. Cary, L.A.; Guan, J.L. Focal adhesion kinase in integrin-mediated signaling. Front. Biosci, 1999, 4, D102-13.
10. Guan, J.L.; Shalloway, D. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature, 1992, 358(6388), 690-2.
11. Kornberg, L.J.; Earp, H.S.; Turner, C.E.; Prockop, C.; Juliano, R.L. Signal transduction by integrins: increased protein tyrosine phosphorylation caused by clustering of beta 1 integrins. Proc. Natl. Acad. Sci. USA, 1991, 88(19), 8392-6.
12. Furuyama, K.; Doi, R.; Mori, T.; Toyoda, E.; Ito, D.; Kami, K.; Koizumi, M.; Kida, A.; Kawaguchi, Y.; Fujimoto, K. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J. Surg., 2006, 30(2), 219-26.
13. Hochwald, S.N.; Nyberg, C.; Zheng, M.; Zheng, D.; Wood, C.; Massoll, N.A.; Magis, A.; Ostrov, D.; Cance, W.G.; Golubovskaya, V.M. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle, 2009, 8(15), 2435-43.
14. Liu, W.; Bloom, D.A.; Cance, W.G.; Kurenova, E.V.; Golubovskaya, V.M.; Hochwald, S.N. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis, 2008, 29(6), 1096-107.
15. Zheng, D.; Golubovskaya, V.M.; Kurenova, E.; Wood, C.; Massoll, N.A.; Ostrov, D.; Cance, W.G.; Hochwald, S.N. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Mol. Carcinog., 2010, 49(2), 200-9.
16. Huanwen, W.; Zhiyong, L.; Xiaohua, S.; Xinyu, R.; Kai, W.; Tonghua, L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol. Cancer, 2009, 8, 125.
17. Slack-Davis, J.K.; Martin, K.H.; Tilghman, R.W.; Iwanicki, M.; Ung, E.J.; Autry, C.; Luzzio, M.J.; Cooper, B.; Kath, J.C.; Roberts, W.G.; Parsons, J.T. Cellular characterization of a novel focal adhesion kinase inhibitor. J. Biol. Chem., 2007, 282(20), 14845-52.
18. Yamamoto, D.; Sonoda, Y.; Hasegawa, M.; Funakoshi-Tago, M.; Aizu-Yokota, E.; Kasahara, T. FAK overexpression upregulates cyclin D3 and enhances cell proliferation via the PKC and PI3- kinase-Akt pathways. Cell Signal, 2003, 15(6), 575-83.
19. Duxbury, M.S.; Ito, H.; Benoit, E.; Zinner, M.J.; Ashley, S.W.; Whang, E.E. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem. Biophys. Res. Commun., 2003, 311(3), 786-92.
20. Duxbury, M.S.; Ito, H.; Zinner, M.J.; Ashley, S.W.; Whang, E.E. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery, 2004, 135(5), 555-62.
21. Golubovskaya, V.M.; Nyberg, C.; Zheng, M.; Kweh, F.; Magis, A.; Ostrov, D.; Cance, W.G. A small molecule inhibitor, 1,2,4,5- benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J. Med. Chem., 2008, 51(23), 7405-16.
22. Schaller, M.D.; Borgman, C.A.; Cobb, B.S.; Vines, R.R.; Reynolds, A.B.; Parsons, J.T. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc. Natl. Acad. Sci. USA, 1992, 89(11), 5192-6.
23. Sieg, D.J.; Hauck, C.R.; Ilic, D.; Klingbeil, C.K.; Schaefer, E.; Damsky, C.H.; Schlaepfer, D.D. FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol., 2000, 2(5), 249-56.
24. Zheng, D.; Kurenova, E.; Ucar, D.; Golubovskaya, V.M.; Magis, A.; Ostrov, D.; Cance, W.G.; Hochwald, S.N. Targeting of the protein interaction site between FAK and IGF-1R. Biochem. Biophys. Res. Commun., 2009; 388(2), 301-5.
25. Roberts, W.G.; Ung, E.; Whalen, P.; Cooper, B.; Hulford, C.; Autry, C.; Richter, D.; Emerson, E.; Lin, J.; Kath, J.; Coleman, K.; Yao, L.; Martinez-Alsina, L.; Lorenzen, M.; Berliner, M.; Luzzio, M.; Patel, N.; Schmitt, E.; LaGreca, S.; Jani, J.; Wessel, M.; Marr, E.; Griffor, M.; Vajdos, F. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res., 2008, 68(6), 1935-44.
26. Siu, B.A.; Mileshkin, L.L.; Camidge, D.R.; Rischin, D.; Chen, E.C.; Jones, S.; Yin, D.; Fingert, H. Phase 1 study of a focal adhesion kinase (FAK) inhibitor PF-00562271 in patients (pts) with advanced solid tumors. J. Clin. Oncol., 2007, 25(18S).
27. Dhani, N.C.; Siu, L.L.; Camidge, D.R.; Mileshkin, L.R.; Xu, H.; Pierce, K.J.; Fahey, N.R.; Fingert, H.J.; Shreeve, S.M. Final report of phase I clinical, pharmacokinectic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors. J. Clin. Oncol., 2010, 28(15), 3028.
28. Chatzizacharias, N.A.; Giaginis, C.; Zizi-Serbetzoglou, D.; Kouraklis, G.P.; Karatzas, G.; Theocharis, S.E. Evaluation of the clinical significance of focal adhesion kinase and SRC expression in human pancreatic ductal adenocarcinoma. Pancreas, 2010, 39(6), 930-6.